Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
暂无分享,去创建一个
Yoshinori Inagaki | Yasuhiko Sugawara | Wei Tang | Keming Zhang | Xiaobin Feng | Qiang Li | P. Song | Wei Tang | K. Hasegawa | K. Ma | Y. Sugawara | N. Kokudo | Ti Zhang | Qiang Li | T. Song | Y. Inagaki | D. Kong | Kiyoshi Hasegawa | Norihiro Kokudo | Peipei Song | Keming Zhang | Xiaobin Feng | Tianqiang Song | Kuansheng Ma | Shuguo Zheng | Zhigang Wang | Dalu Kong | Qiang Wu | Ti Zhang | Xin Zhao | Shu-guo Zheng | Qiang Wu | Zhigang Wang | Xin Zhao | W. Tang
[1] J. Bruix,et al. Biomarkers for early diagnosis of hepatocellular carcinoma. , 2012, The Lancet Oncology.
[2] S. Nakano,et al. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. , 1999, European journal of gastroenterology & hepatology.
[3] H. Liebman,et al. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. , 1993, Hepatology.
[4] J. Avery. Critical review. , 2006, The Journal of the Arkansas Medical Society.
[5] J. Kao,et al. Prevention of hepatocellular carcinoma in the Asia–Pacific region: Consensus statements , 2010, Journal of gastroenterology and hepatology.
[6] J. Marrero. Screening tests for hepatocellular carcinoma. , 2005, Clinics in liver disease.
[7] C. Legnani,et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. , 1995, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[8] J. Marrero. Hepatocellular carcinoma. , 2005, Current opinion in gastroenterology.
[9] M. Omata,et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review , 2008, Hepatology international.
[10] S. Saab,et al. Des‐γ‐carboxyprothrombin, α‐fetoprotein and AFP‐L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma , 2008, Journal of gastroenterology and hepatology.
[11] P. Song,et al. Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. , 2013, Hepatobiliary surgery and nutrition.
[12] J. Marrero,et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. , 2009, Gastroenterology.
[13] Jianjun Gao,et al. Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China , 2013, Liver Cancer.
[14] J. Marrero,et al. Des‐gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients , 2003, Hepatology.
[15] Zhao-You Tang,et al. Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.
[16] T. Ogihara,et al. Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes , 1993, Digestive Diseases and Sciences.
[18] A. Burroughs,et al. Hepatocellular carcinoma , 2003, The Lancet.
[19] N. Izumi. Diagnostic and Treatment Algorithm of the Japanese Society of Hepatology: A Consensus-Based Practice Guideline , 2010, Oncology.
[20] B. Furie,et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. , 1984, The New England journal of medicine.
[21] Y. Ueno,et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. , 2000, The American journal of gastroenterology.
[22] Jin-Lin Hou,et al. Hepatocellular carcinoma in the Asia pacific region , 2009, Journal of gastroenterology and hepatology.
[23] G. Casazza,et al. Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review , 2006, The American Journal of Gastroenterology.
[24] P. Song,et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011 , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[25] Shou-Dong Lee,et al. Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma , 1984 .
[26] B. Daniele,et al. α-fetoprotein and ultrasonography screening for hepatocellular carcinoma , 2004 .
[27] K. Taketa,et al. Determination of Optimum Cutoff Levels of Plasma Des-γ-Carboxy Prothrombin and Serum α-Fetoprotein for the Diagnosis of Hepatocellular Carcinoma using Receiver Operating Characteristic Curves , 1992 .
[28] D. Amarapurkar,et al. Application of surveillance programs for hepatocellular carcinoma in the Asia–Pacific Region , 2009, Journal of gastroenterology and hepatology.
[29] J. Hoofnagle,et al. Elevations in serum alpha‐fetoprotein levels in patients with chronic hepatitis B , 1989, Cancer.
[30] K. Tanikawa,et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. , 2000, Oncology reports.
[31] Hideo Tanaka,et al. Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures , 2011, Journal of epidemiology.
[32] H. Ding,et al. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. , 2002, Chinese medical journal.
[33] B. Daniele,et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. , 2004, Gastroenterology.
[34] Yuesi Zhong,et al. Strategies to prevent hepatitis B virus infection in China: immunization, screening, and standard medical practices. , 2013, Bioscience trends.
[35] Jacques Ferlay,et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .
[36] S. Fujiyama,et al. Clinical usefulness of des-γ-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma , 1991, Digestive Diseases and Sciences.
[37] H. Liebman,et al. Des‐γ‐carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review , 1993 .
[38] Yoichi M. Ito,et al. Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size , 2006, The American Journal of Gastroenterology.
[39] H. Ding,et al. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to α-fetoprotein , 2003, British Journal of Cancer.